U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H24N4O6S2
Molecular Weight 420.504
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DORIPENEM

SMILES

C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O

InChI

InChIKey=AVAACINZEOAHHE-VFZPANTDSA-N
InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1

HIDE SMILES / InChI

Description
Sources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdf
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1

Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.

CNS Activity

Curator's Comment: Doripenem penetrates the intact blood-brain barrier to a small but measurable extent.

Originator

Curator's Comment: Shionogi (Japan) is the drug's originator and markets doripenem under the brand name Finibax. Peninsula Pharmaceuticals acquired development and marketing rights to doripenem in the US in a licensing agreement signed with Shionogi in 2003. Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Pharmaceuticals in 2005.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
47.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.87 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.94 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.2 mg/L
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
23 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
66.4 mg*h/L
1000 mg 3 times / day multiple, intravenous
dose: 1000 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex: UNKNOWN
food status: UNKNOWN
47.1 mg*h/L
500 mg 3 times / day multiple, intravenous
dose: 500 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex: UNKNOWN
food status: UNKNOWN
52.98 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.64 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.8 mg × h/L
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
36.3 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
1000 mg 3 times / day multiple, intravenous
dose: 1000 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex: UNKNOWN
food status: UNKNOWN
2.2 h
500 mg 3 times / day multiple, intravenous
dose: 500 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex: UNKNOWN
food status: UNKNOWN
2.93 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.04 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.91 h
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
91.9%
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Disc. AE: Transaminases increased, Allergic reaction...
Other AEs: Leukopenia, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Allergic reaction (1 patient)
Other AEs:
Leukopenia (1 patient)
Diarrhea (11 patient)
Nausea (9 patients)
Vomiting (9 patients)
Headache (6 patients)
Oral candidiasis (3 patients)
Rash (2 patients)
Sources:
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Sources:
Disc. AE: Nausea, Vulval mycotic infection...
AEs leading to
discontinuation/dose reduction:
Nausea (0.2%)
Vulval mycotic infection (0.1%)
Rash (0.1%)
Sources:
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Other AEs: Anemia neonatal, Hypoalbuminemia...
Other AEs:
Anemia neonatal (3 patients)
Hypoalbuminemia (3 patients)
Hyperglycemia (2 patients)
Peripheral edema (1 patient)
Patent ductus arteriosus (2 patients)
Sources:
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Sources:
Other AEs: Anemia neonatal, Peripheral edema...
Other AEs:
Anemia neonatal (1 patient)
Peripheral edema (1 patient)
Dermatitis diaper (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Leukopenia 1 patient
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Allergic reaction 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Transaminases increased 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Diarrhea 11 patient
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Rash 2 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Oral candidiasis 3 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Headache 6 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Nausea 9 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Vomiting 9 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
Health Status: unhealthy
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Sources:
Rash 0.1%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Sources:
Vulval mycotic infection 0.1%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Sources:
Nausea 0.2%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Sources:
Peripheral edema 1 patient
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Hyperglycemia 2 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Patent ductus arteriosus 2 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Anemia neonatal 3 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Hypoalbuminemia 3 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Sources:
Anemia neonatal 1 patient
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Sources:
Peripheral edema 1 patient
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Sources:
Dermatitis diaper 2 patients
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Doripenem: S 4661.
2003
Gateways to clinical trials.
2003 Dec
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
2004 Aug
Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats.
2004 Dec
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
2004 Jul
Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit.
2005 May
Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
2005 Oct
Acquisitions not a cure for anti-infectives.
2005 Sep
Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem.
2006 Dec
Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals.
2006 Jan-Feb
Doripenem.
2006 Jun
Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.
2006 Sep 1
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
2007 Dec
Biochemical characterisation of the CTX-M-14 beta-lactamase.
2007 Feb
Carbapenems in the USA: focus on doripenem.
2007 Oct
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.
2008
Doripenem: a review of its use in the treatment of bacterial infections.
2008
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?
2008
[Clinical examination of doripenem for infectious diseases in gynecological and associated fields].
2008 Apr
Gateways to clinical trials. December 2008.
2008 Dec
New developments in carbapenems.
2008 Dec
What's new and not so new on the antimicrobial horizon?
2008 Dec
[In-vitro activity of panipenem against clinical isolates in 2006].
2008 Feb
Carbapenems: a potent class of antibiotics.
2008 Jan
Doripenem (Doribax)--a new parenteral carbapenem.
2008 Jan 28
New drugs: doripenem, raltegravir, and ixabepilone.
2008 Jan-Feb
Doripenem (Doribax): the newest addition to the carbapenems.
2008 Jul
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.
2008 Mar
Current status of newer antiinfectives.
2008 Nov
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.
2008 Nov
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
2008 Oct
Current treatment of pseudomonal infections in the elderly.
2009
Current status of newer carbapenems.
2009
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
2009 Apr
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
2009 Apr
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.
2009 Aug
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
2009 Feb
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
2009 Jan
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
2009 Jul
An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible.
2009 Jul
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.
2009 Mar
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf
Curator's Comment: Administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age. For complicated intra-abdominal infection 5-14 days, for complicated UTI, including pyelonephritis 10 days.
500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age; for complicated intra-abdominal infection 5–14 days, for complicated UTI, including pyelonephritis 10 days.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.accessdata.fda.gov/cdrh_docs/reviews/k080019.pdf
HardyDisk™ Doripenem Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. The concentration of doripenem 10ug has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius
Name Type Language
DORIBAX
Preferred Name English
DORIPENEM
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DORIPENEM [EMA EPAR]
Common Name English
DORIPENEM [MART.]
Common Name English
doripenem [INN]
Common Name English
DORIPENEM [USAN]
Common Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-(((3S,5S)-5-(((AMINOSULFONYL)AMINO)METHYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-, (4R,5S,6S)-
Common Name English
(+)-(4R,5S,6S)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-3-(((3S,5S)-5-((SULFAMOYLAMINO)METHYL)-3-PYRROLIDINYL)THIO)-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
DORIPENEM [VANDF]
Common Name English
DORIPENEM [ORANGE BOOK]
Common Name English
Doripenem [WHO-DD]
Common Name English
S-4661
Code English
DORIPENEM [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000175496
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NCI_THESAURUS C260
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
EMA ASSESSMENT REPORTS DORIBAX (WITHDRAW: URINARY TRACT INFECTIONS)
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
FDA ORPHAN DRUG 188104
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
WHO-ATC J01DH04
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
NDF-RT N0000011294
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
LIVERTOX NBK548111
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
WHO-VATC QJ01DH04
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
Code System Code Type Description
MESH
C099245
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
NCI_THESAURUS
C65470
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID2046678
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
FDA UNII
BHV525JOBH
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
DRUG CENTRAL
4149
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
DRUG BANK
DB06211
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
MERCK INDEX
m4744
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY Merck Index
USAN
RR-37
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
EVMPD
SUB22196
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL491571
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
CAS
148016-81-3
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
LACTMED
Doripenem
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
RXCUI
119771
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY RxNorm
PUBCHEM
73303
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
INN
7975
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
SMS_ID
100000089808
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY
WIKIPEDIA
DORIPENEM
Created by admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
PRIMARY